Back to top
more

ACADIA Pharmaceuticals (ACAD)

(Real Time Quote from BATS)

$14.61 USD

14.61
840,299

-0.12 (-0.82%)

Updated Oct 8, 2024 02:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Ardelyx (ARDX) Up on Xphozah's Orphan Tag for Hyperphosphatemia

Ardelyx (ARDX) announces that the FDA has granted orphan drug designation to Xphozah for the treatment of pediatric hyperphosphatemia. The stock rises 4%.

Implied Volatility Surging for On ACADIA Pharmaceuticals (ACAD) Stock Options

Investors need to pay close attention to ACADIA Pharmaceuticals (ACAD) stock based on the movements in the options market lately.

Esperion (ESPR) Q3 Earnings Beat, Stock Up on Strong Revenues

Esperion's (ESPR) third-quarter earnings and revenues beat estimates on the back of better-than-expected collaboration revenues. The company reiterates its financial guidance for 2023.

Sage Therapeutics (SAGE) Q3 Earnings Lag Estimates, Down 5%

Sage Therapeutics (SAGE) reports dismal third-quarter results. It intends to price the recently approved oral postpartum depression pill Zurzuvae at $15,900 for an entire 14-day treatment course.

Iovance's (IOVA) Meets Q3 Earnings, Lags Sales Estimates

Iovance's (IOVA) third-quarter earnings meet estimates, but sales miss the same.

Perrigo (PRGO) Lags on Q3 Earnings & Sales, Lowers '23 View

Perrigo (PRGO) reports dismal third-quarter 2023 results. Management lowers guidance for earnings and sales. Stock price drops 5% post the announcement.

CRISPR Therapeutics (CRSP) Q3 Loss Narrower Than Expected

CRISPR Therapeutics (CRSP) beats the mark for earnings and misses the same for sales in the third quarter.

Agios (AGIO) Reports Narrower-Than-Expected Q3 Loss, Lags Sales

Agios' (AGIO) Q3 earnings beat estimates, but sales miss the same.

Karuna's (KRTX) Q3 Loss Wider-Than-Expected, Sales Miss

Karuna's (KRTX) third-quarter 2023 earnings miss estimates. The company did not record any sales during the quarter.

Allogene's (ALLO) Q3 Loss Narrower Than Expected, Sales Miss

Allogene's (ALLO) third-quarter earnings beat estimates, but sales miss the same. Management reiterated its previously issued financial guidance for 2023.

Acadia (ACAD) Q3 Earnings and Sales Beat Estimates, Stock Up

Acadia (ACAD) reports better-than-expected third-quarter 2023 results as both earnings and sales beat estimates. The stock rises in after-market hours.

Is Medpace (MEDP) Outperforming Other Medical Stocks This Year?

Here is how Medpace (MEDP) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.

Novo Nordisk (NVO) to Report Q3 Earnings: What's in the Cards?

Novo Nordisk (NVO) is likely to outperform third-quarter 2023 estimates, driven by increased Diabetes and Obesity Care product sales despite severe rivalry and pricing pressure in the United States.

STERIS (STE) Set to Post Q2 Earnings: What's in the Cards?

STERIS' (STE) second-quarter fiscal 2024 results are likely to reflect an impressive performance across the Healthcare and AST segments.

Perrigo (PRGO) to Report Q3 Earnings: What's in the Cards?

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.

Viatris (VTRS) to Report Q3 Earnings: Is a Beat in Store?

Viatris' (VTRS) Q3 results are likely to have been boosted by the momentum in its branded and generic businesses.

Gilead (GILD) Gears Up to Report Q3 Earnings: What's in Store?

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its third-quarter 2023 results.

Will Zimmer Biomet (ZBH) Beat Estimates This Earnings Season?

Zimmer Biomet (ZBH) is expected to have witnessed strong performance across Avenir Complete hip.

Hologic (HOLX) Q4 Earnings Might Rise on 7.7% Breast Health Growth

Strength in Breast Health and growing Panther instrument installed base will likely benefit Hologic's (HOLX) Q4 performance.

Vertex (VRTX) to Report Q3 Earnings: What's in the Cards?

Vertex (VRTX) is likely to outperform third-quarter 2023 estimates, driven by the increased international sales of its lead drug, Trikafta/Kaftrio.

Henry Schein (HSIC) Set to Post Q3 Earnings: What Awaits?

Henry Schein's (HSIC) third-quarter 2023 results are likely to reflect the strong fundamentals of the Dental business.

Incyte (INCY) to Report Q3 Earnings: What's in the Cards?

Higher sales of lead drug Jakafi and incremental sales of newly approved drugs are likely to have boosted Incyte's (INCY) top line during the third quarter of 2023.

How Much Upside is Left in Acadia (ACAD)? Wall Street Analysts Think 38.62%

The consensus price target hints at a 38.6% upside potential for Acadia (ACAD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Hologic (HOLX) to Report Q4 Earnings: What's in the Cards?

Strength in Breast Health and GYN Surgical businesses will likely drive Hologic's (HOLX) Q4 revenues.

Regeneron (REGN) to Report Q3 Earnings: What's in the Cards?

Investors' focus is likely to be on the performance of lead drug Eylea and the uptake of Eylea HD when Regeneron (REGN) reports its third-quarter 2023 results.